The Hessian Biotech service provider, Biotest is aiming for accelerated approval of its drug Trimodulin to be used in severe Covid-19-disease. First, the study was submitted to the authorities in Spain and by the competent Ethics Committee, such as Biotest announced. To the start of the week Biontech from Mainz to receive the so-called Fast-Track Status for two of its vaccine candidate against the Coronavirus.
In this Phase II study should be about 160 adults, seriously ill Covid-19 patients included. There are already promising results in artificially ventilated patients with high inflammation values obtained, it said.
Biotest hopes on a fast-track admission process to the medicine as quickly as possible. You see “a substantial Potential” for the treatment of patients with the Virus-induced lung inflammation, said Andrea Wartenberg-Demand from the Biotest Board of management.
